PTC Therapeutics, Inc. (PTCT)
UndervaluedFundamental
57
Price
$60.59
Market Cap
$5.23B
Part 1 · What the company is worth
Overview
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance Sheet & Liquidity
Revenue
$1.01B
Trailing 12 months (through 6/30/2026)
Net Income
$-38M
Trailing 12 months (through 6/30/2026)
Free Cash Flow
$702M
Total Equity
$-205M
Total Liabilities
$3.10B
Current Ratio
3.39
Interest Coverage
-
Debt/EBITDA
0.77
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$150.11
Current Price
$60.59
Margin of Safety
+59.6%
Fair Value Range
$97.57 - $202.65
Spread across the valuation methods used, not a statistically calibrated confidence interval.
Estimation Methods
Valuation Metrics
P/E Ratio
8.05
ROE
-332.5%
P/B Ratio
-
P/FCF
7.44
Gross Margin
-
ROIC
4.0%
Profitability Radar
Value Creation (Economic Moat)
ROIC
4.0%
WACC
7.1%
ROIC − WACC
-3.1 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental Analysis Criteria
Passed (9)
- EPS shows upward trend
- Price CAGR 19.04%
- P/FCF 7.44
- Operating margin 12.5%
- Current ratio
- Debt/EBITDA
- DCF valuation (Undervalued)
- Revenue growth 5Y 135.4%
- Piotroski F-Score 6/9
Failed (9)
- EPS CAGR 3.91%
- ROIC 4.0%
- Positive free cash flow
- Return on tangible assets
- Low reliance on intangibles
- ROE -351.9%
- Earnings surprise, average -1,034.0%
- Share dilution 14.2%
- Net margin trend -3.8% vs 35.6%
Unavailable (9)
- Gross margin –
- P/B ratio –
- Dividend payout –
- Debt/equity ratio
- CapEx intensity
- Interest coverage
- Price below Graham Number
- PEG ratio (needs P/E > 0 and growth > 0)
- Earnings quality (operating cash flow / net income)
Piotroski F-Score
Mixed signals: some areas need attention
Earnings Quality
Low quality: investigate accounting
Share Dilution
Issuing new shares, diluting ownership
Institutional Holdings
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Dr. Matthew B. Klein F.A.C.S., M.D., M.S. | CEO & Director | 53 |
| Dr. Allan Steven Jacobson Ph.D. | Co-Founder & Independent Director | 79 |
| Mr. Pierre Gravier M.S. | Chief Financial Officer | 40 |
| Dr. Neil Almstead Ph.D. | Chief Technical Operations Officer | 58 |
| Mr. Eric Pauwels | Chief Business Officer | 63 |
| Dr. Lee Scott Golden M.D., Ph.D. | Executive VP & Chief Medical Officer | 57 |
| Ms. Christine Utter CPA | Senior VP, Chief Accounting Officer & Head of People Services | 46 |
| Ms. Linda Montella Carter | Senior VP & Chief Information Officer | - |
| Ms. Ellen Cavaleri | Head of Investor Relations | - |
| Mr. Mark Elliott Boulding J.D. | Executive VP & Chief Legal Officer | 64 |
Audit Risk
3
Board Risk
3
Compensation Risk
4
Shareholder Rights Risk
7
Documents
- View document
Annual Report (10-K)
A yearly overview of the business, its financial results, and the risks it faces.
Filed on 2026-02-19
- View document
Quarterly Report (10-Q)
A snapshot of financial performance for the most recent three-month period.
Filed on 2026-07-30
- View document
Current Report (8-K)
An announcement of a major event, such as a leadership change or big news.
Filed on 2026-09-21
via SEC EDGAR
Income History
via SEC EDGAR
Part 2 · The price and its context
This part shows how the price has behaved, not whether the company is worth owning. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Market Reaction Profile
How much PTCT moves, measured on its daily prices.
More volatile than 60% of the tracked stocks (90-day volatility).
- Volatility 30d
- 39.7%
- Volatility 90d
- 40.2%
- Beta vs S&P 500 (1y)
- 0.70Correlation 0.22
- Max drawdown (12m)
- -33.8%
- ATR (14d, % of price)
- 3.61%
Earnings reactions
How PTCT moved around its past quarterly results.
Next earnings release
Oct 29, 2026 · In 5 days · After the close
EPS estimate: 0.30Revenue estimate: $305M
What usually happens
- Over the last 12 releases the stock moved a median of 9.9% the next day, up or down.
- Next-day moves: up 8, down 4 (out of 12).
Release history
| Date | When | EPS est. | EPS actual | Surprise | Gap | 1 day | 5 days |
|---|---|---|---|---|---|---|---|
| Jul 30, 2026 | After the close | 0.43 | 0.92 | +116.4% | -6.1% | -9.9% | -6.2% |
| May 7, 2026 | After the close | -0.48 | -0.03 | +93.7% | +14.9% | +14.3% | +12.8% |
| Feb 19, 2026 | After the close | 0.04 | -1.67 | -4460.3% | -2.1% | +1.1% | -2.6% |
| Nov 4, 2025 | After the close | -1.40 | 0.20 | +114.3% | +3.4% | +6.0% | +9.0% |
| Aug 7, 2025 | After the close | n/a | n/a | n/a | -10.6% | -9.9% | -3.3% |
| May 6, 2025 | After the close | n/a | n/a | n/a | +8.9% | +12.6% | +28.2% |
| Feb 27, 2025 | After the close | n/a | n/a | n/a | -10.1% | +9.3% | +4.4% |
| Nov 7, 2024 | After the close | n/a | n/a | n/a | +6.2% | +3.1% | -1.4% |
| Aug 8, 2024 | After the close | n/a | n/a | n/a | -9.5% | -3.6% | +1.8% |
| Apr 25, 2024 | After the close | n/a | n/a | n/a | +5.9% | +12.1% | +31.9% |
| Feb 29, 2024 | After the close | n/a | n/a | n/a | -6.0% | +13.3% | +9.1% |
| Oct 26, 2023 | After the close | n/a | n/a | n/a | -19.2% | -22.7% | -24.6% |
Release dates from SEC 8-K filings.
Updated 10/24/2026
Historical statistics for educational purposes only. They are not forecasts and not investment advice.
Price reaction to the news
Latest news on PTCT and what the price did next.
- 3/3/2026PositiveInvestment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing
Published while the US market was open: the move of that day cannot be split into before and after the news, so no figure is shown.
Return of the stock minus return of SPY over the same days. A news item close to a price move did not necessarily cause it. Historical data for educational purposes only, not investment advice.
Latest News
Recent headlines for PTCT.
- 3/3/2026POSITIVEInvestment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing
Investor confidence in PTC Therapeutics (PTCT) appears to be on the rise, following a recent SEC filing that disclosed a significant purchase of 41,000 shares by an investment manager. This strategic move suggests a positive outlook on the future of the company, which specializes in developing therapies for rare diseases. The increased stake by an institutional player can be interpreted as a bullish signal, indicating that the market might be underestimating the potential of PTC Therapeutics' portfolio of commercial products and investigational candidates. Investors should closely monitor the stock's performance, as such an endorsement often precedes positive price movements, reflecting stronger conviction in the company's business model and long-term growth prospects within the biopharmaceutical sector.